Ticketmaster Agrees to Update and Strengthen Website to Comply with Digital Advertising Alliance’s Self-Regulatory Principles

McLean, VA – June 13, 2023 - BBB National Programs’ Digital Advertising Accountability Program (DAAP) worked with Ticketmaster Entertainment, LLC to bring its website into compliance with the Digital Advertising Alliance’s (DAA) Self-Regulatory Principles. 

DAAP monitors the digital marketplace for compliance with digital advertising best practices related to interest-based advertising (IBA) across websites and mobile apps. Following a consumer complaint, DAAP conducted a review of Ticketmaster's website privacy practices and found the website Ticketmaster.com, which engaged in third-party data collection by companies known to engage in IBA, was not compliant with the DAA’s Transparency Principle. 

In response to DAAP’s inquiry, Ticketmaster conducted a comprehensive review to strengthen its compliance protocols and ensure they comply with DAA Principles. Ticketmaster:

  • Updated its primary website footer to include a prominent and conspicuous link directing users to the Ad Choices page, providing enhanced notice, opt-out tools, and a statement of adherence to DAA Principles. 
  • Incorporated changes to reflect Enhanced Notice through its Consent Management Platform (CMP) by providing additional links to third-party opt-out tools and disclosure of third-party interest-based advertising. The link to the CMP is accessible from all web pages on the Ticketmaster domain.
  • To meet first-party enhanced notice requirements, committed to updating its secondary website footer by changing the existing "Manage My Cookies" link to read "Manage My Cookies and Ad Choices." DAAP will continue to monitor this change until it is made. 

 

In its advertiser statement, Ticketmaster agreed to comply with DAAP’s recommendations and stated “Ticketmaster’s goal is to maintain the trust and confidence of its consumers by complying with global data protection laws to the highest standard and being transparent when it comes to the processing of our consumer’s data. We commend the Digital Advertising Accountability Program’s similar mission and dedication to compliance with the DAA self-regulatory requirements.”

All BBB National Programs case decision summaries can be found in the case decision library. For the full text of DAAP decisions, visit the DAAP Decisions and Guidance webpage.

 

Subscribe to the Ad Law Insights or Privacy Initiatives newsletters for an exclusive monthly analysis and insider perspectives on the latest trends and case decisions in advertising law and data privacy.

 

 

 

 

Latest Decisions

Decision

National Advertising Division Recommends Dr. Luke Healthcare Discontinue Treatment Claims for its Fungal Nail Renewal Product

New York, NY – July 24, 2024 – The National Advertising Division recommended Dr. Luke Healthcare discontinue certain claims for Dr. Luke’s Fungal Nail Renewal product, including health-related claims, natural claims, and claims that a doctor recommends the product or that it treats a medical condition.

Read the Decision Summary
Decision

National Advertising Division Finds Flag Image on Kendamil Infant Formula Packaging Conveys Supported Message about Products’ Origin

New York, NY – July 17, 2024 – In a Fast-Track SWIFT challenge, the National Advertising Division determined that use of a flag image on product packaging for Kendal Nutricare’s Kendamil infant formula reasonably conveys a supported message about the products’ origin. 

Read the Decision Summary
Decision

In National Advertising Division Case, GuruNanda Voluntarily Discontinues Claims Made through Influencers for Coconut Pulling Oil Products

New York, NY – July 16, 2024 – The National Advertising Division has closed a Fast-Track SWIFT challenge regarding claims that GuruNanda’s coconut pulling oil products can “naturally reverse a cavity” and “reverse cavities.” 

Read the Decision Summary
Decision

National Advertising Division Refers Health-Related Advertising Claims for Prolacta’s Human Milk Fortifier to Regulatory Agencies

New York, NY – July 15, 2024 – The National Advertising Division will refer advertising claims made by Prolacta Bioscience for its Human Milk Fortifier to the Federal Trade Commission (FTC) and Food and Drug Administration (FDA) for review.

Read the Decision Summary